Antiandrogen Withdrawal Alone or in Combination With Ketoconazole in Androgen-Independent Prostate Cancer Patients: A Phase III Trial (CALGB 9583)

Eric J. Small(CancerCare Manitoba), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Joel Picus(Washington University in St. Louis), Susan Halabi(Duke University), Frank M. Torti(UConn Health), Walter M. Stadler(University of Maryland, Baltimore), Ellen B. Kaplan(University of Maryland, Baltimore), Preston Gable(University of Maryland, Baltimore), Nancy A. Dawson(University of Maryland, Baltimore), Brian I. Rini(CancerCare Manitoba)
Journal of Clinical Oncology
March 12, 2004
10.1200/jco.2004.06.037
Cited by 502

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k